Today: 12 June 2026
Browse Category

NASDAQ:CDE 11 June 2026

Stock Market Today

  • Stocks Surge on Iran Peace Hopes, Oil Prices Drop
    June 11, 2026, 5:57 PM EDT. Stocks rallied to their best day in two months as President Trump called off threats to bomb Iran, raising hopes for a deal to resume global oil flows. The S&P 500 jumped 1.8%, Dow rose 1.9%, and Nasdaq gained 2.5%. A possible peace deal could reopen the Strait of Hormuz, a key oil shipping route, pushing U.S. crude prices down 2.6% to $87.71 a barrel. High oil prices had contributed to inflation, with U.S. wholesale prices rising more than expected in May. The market also saw volatility in artificial intelligence (AI) stocks, with chipmakers like Marvell Technology soaring following mixed swings. Higher interest rates by the European Central Bank aimed to curb inflation but could slow economic growth and impact investment valuations.

Latest articles

Bradesco Shares Rise, BBDC4 and BBD ADRs Track Brazil Market Recovery

Bradesco Shares Rise, BBDC4 and BBD ADRs Track Brazil Market Recovery

11 June 2026
Bradesco’s preferred shares jumped to R$17.67 and U.S. ADRs to $3.44 with heavy volume as Brazil’s Ibovespa surged 1.71%, spotlighting the lender after reporting a 16.1% year-over-year rise in recurring net income to R$6.811 billion in 1Q26; board and executive insiders sold non-voting shares, while the controlling group’s stake remained unchanged.
Bank of Nova Scotia Hits 52-Week High; TSX Bounces Back

Bank of Nova Scotia Hits 52-Week High; TSX Bounces Back

11 June 2026
Bank of Nova Scotia surged to a 52-week high, closing up 1.24% at C$115.27 in Toronto after announcing expanded AI adoption across its workforce and higher Q2 earnings, while the S&P/TSX Composite jumped 1.5% as financials rallied and trading volume soared above average.
Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

11 June 2026
Moderna surged 7.94% to $49.64 as U.S. stocks rebounded sharply, with investors eyeing its mRNA cancer-vaccine pipeline after a UK trial authorization; Wall Street’s average analyst rating remains “Hold” with a $43.30 target, and BofA raised its price target to $34 citing norovirus prospects, while Moderna reported Q1 revenue of $389 million and a $1.3 billion net loss.
Go toTop